Search - tctmd.com

Displaying 1 - 20 of 31

Sort: Relevancy | Date

News Conference News EuroPCR 2024

Coronary Access More Challenging With Self-Expanding Valves: SCAAR/SWENTRY

Michael O'Riordan

May 17, 2024

News Conference News ESC 2023

ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More

Michael O'Riordan

September 06, 2023

News Conference News LINC 2023

PROSPECT MONSTER: Real-World Data Confirm Low-Dose DCB Efficacy in PAD

L.A. McKeown

June 21, 2023

News Conference News LINC 2023

Early Data on Temporary Spur in BTK PAD Show Efficacy, Limited Recoil

L.A. McKeown

June 09, 2023

News Daily News

Failure to Access Coronaries After TAVR Almost Exclusive to CoreValve Evolut

Michael O'Riordan

October 28, 2020

News Conference News LINC 2020

Algorithm Aims to Help Operators Pair Laser Settings With PAD Lesion Type

L.A. McKeown

February 06, 2020

News Conference News LINC 2020

DCBs Show Consistent Long-term Benefits in Complex Fem-Pop Patient Subsets

L.A. McKeown

January 30, 2020

News Conference News LINC 2020

Lutonix BTK Studies: Below-the-Knee Challenges Linger

L.A. McKeown

January 29, 2020

News Conference News LINC 2020

COMPARE: Similar Efficacy and Safety for Paclitaxel Balloons Regardless of Dose

L.A. McKeown

January 28, 2020

News Conference News CRT 2019

Acknowledgment of Safety Signal for Paclitaxel Devices in PAD May Mark Sea Change in Controversy

L.A. McKeown

March 06, 2019

News Daily News

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

L.A. McKeown

January 25, 2019

News Daily News

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

L.A. McKeown

January 23, 2019

News Daily News

Multivessel PCI Improves Outcomes in STEMI Patients With Cardiogenic Shock: Korean Registry

Caitlin E. Cox

February 23, 2018

News Daily News

REAL PTX: Head-to-Head DCB, DES Data in PAD Show Trend Favoring Stenting at 36 Months

L.A. McKeown

February 11, 2018

News Industry News

SELUTION™ First-in-Man Study Achieves Primary Endpoint

January 31, 2018

News Conference News TCT 2017

No Advantage With Hybrid Revascularization for Multivessel Disease: HREVS

Michael O'Riordan

October 30, 2017

News Conference News TCT 2017

Live From Denver: TCT 2017, Day One

Shelley Wood

October 30, 2017

News Daily News

Early Invasive Strategy Benefits Select High-Risk NSTE ACS Patients, Meta-analysis Suggests

Michael O'Riordan

August 14, 2017

News Industry News

First Drug-Coated Balloon (DCB) Study Results in Japan Demonstrate Consistent Clinical Outcomes with Other Medtronic DCB Studies

February 09, 2017

News Conference News ESC 2016

NIPPON: With Nobori Stent, 6 Months of DAPT as Safe and Effective as 18 Months

Michael O'Riordan

August 28, 2016

Advertisement

Coronary Access More Challenging With Self-Expanding Valves: SCAAR/SWENTRY

ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More

PROSPECT MONSTER: Real-World Data Confirm Low-Dose DCB Efficacy in PAD

Early Data on Temporary Spur in BTK PAD Show Efficacy, Limited Recoil

Failure to Access Coronaries After TAVR Almost Exclusive to CoreValve Evolut

Algorithm Aims to Help Operators Pair Laser Settings With PAD Lesion Type

DCBs Show Consistent Long-term Benefits in Complex Fem-Pop Patient Subsets

Lutonix BTK Studies: Below-the-Knee Challenges Linger

COMPARE: Similar Efficacy and Safety for Paclitaxel Balloons Regardless of Dose

Acknowledgment of Safety Signal for Paclitaxel Devices in PAD May Mark Sea Change in Controversy

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

Multivessel PCI Improves Outcomes in STEMI Patients With Cardiogenic Shock: Korean Registry

REAL PTX: Head-to-Head DCB, DES Data in PAD Show Trend Favoring Stenting at 36 Months

SELUTION™ First-in-Man Study Achieves Primary Endpoint

No Advantage With Hybrid Revascularization for Multivessel Disease: HREVS

Live From Denver: TCT 2017, Day One

Early Invasive Strategy Benefits Select High-Risk NSTE ACS Patients, Meta-analysis Suggests

First Drug-Coated Balloon (DCB) Study Results in Japan Demonstrate Consistent Clinical Outcomes with Other Medtronic DCB Studies

NIPPON: With Nobori Stent, 6 Months of DAPT as Safe and Effective as 18 Months

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content